Xianju Pharmaceutical's vecuronium bromide proposed for national procurement

Zhejiang Xianju Pharmaceutical Co. Ltd. has confirmed that its injectable vecuronium bromide is proposed for selection in the eleventh batch of national centralized drug procurement. The company participated in the bidding process from October 27 to October 28, 2025. The proposed price for the 4mg powder for injection is CNY 2.24 per vial.

This selection would see the product supplied to key provinces including Jiangsu, Zhejiang, Shaanxi, Jilin, Heilongjiang, and Liaoning. The procurement period is set to run from the effective date of the selection results until December 31, 2028, with annual agreements based on prior year's committed volumes.

In 2024, the injectable vecuronium bromide generated sales revenue of CNY 1,769.15m, representing 0.44% of the company's total annual operating income. For the first nine months of 2025, sales reached CNY 1,418.40m, accounting for 0.50% of the company's operating income for that period. The company acknowledges that while the new pricing is lower, this inclusion is expected to enhance drug accessibility and strengthen its brand influence. However, the final impact on future performance remains uncertain pending definitive procurement agreements.